
· Executive Brief
National Atrial Fibrillation Awareness Month 2026
Use the observance to review how people find information, enter the right route, and remain connected through follow-through.

Leadership signal
Recognition becomes useful when leaders inspect the real route.
The strongest use of the observance is operational. Map where questions enter, how requests move, when ownership changes, and how unresolved work becomes visible. The goal is not to make a clinical claim. It is to make the organization’s response easier to understand and manage.
Start by distinguishing what is known from what the organization still needs to learn. A campaign plan, communication volume, or meeting count does not establish that a route is usable. Leaders need direct listening, clear ownership, locally defined measures, and a method for keeping exceptions visible.
Executive opening
Atrial fibrillation is a pathway problem that ends in preventable strokes
Atrial fibrillation is often silent until a stroke occurs. That makes it an operations challenge for health systems: people must be found, confirmed, offered stroke prevention, and supported over years. Each step depends on a handoff between settings that are rarely managed as one pathway. Many of those handoffs cross organizational lines, from a pharmacy counter or a smartwatch alert to a primary care inbox and then to a specialist clinic.
The evidence reviewed for this brief shows that the weakest points are often after detection. In a nationwide Finnish registry, 64.3% of patients with atrial fibrillation who had a first ischemic stroke were not taking an oral anticoagulant at the time.[7] In a Japanese pharmacy screening program, pharmacists recommended medical consultation for 49% of possible cases, but few physicians reported seeing referred patients.[3] Finding the arrhythmia is not the same as preventing the stroke. For executives, that distinction matters because the costliest failures happen after the organization already knows a patient has the condition.
Simple fixes have not closed the gap on their own. A large pragmatic trial that mailed educational material to patients and clinicians found no meaningful change in anticoagulant initiation at one year.[14] Mobile integrated care also did not reduce unplanned hospitalizations in an older, already well-managed population.[10] These results argue for redesigning the route, not just adding messages or apps. They also suggest that the right intervention depends on where a given system is losing patients.
This brief adds the research base behind the executive guidance on this page. It covers burden and detection, the continuum from screening to treatment, access through pharmacies and risk-guided screening, equity, the workforce that runs the pathway, and communication that supports real decisions. The aim is one measurable improvement that holds after September.
Current evidence
What the research says about detection and stroke prevention gaps
Undertreatment remains the central problem. Among 174,094 patients with new-onset atrial fibrillation in Finland from 2007 to 2017, 11,680 (6.7%) had an ischemic stroke.[7] Of those strokes, 7,507 (64.3%) occurred in patients who were not on oral anticoagulation, although that share fell from 77.2% to 45.6% over the study period.[7] The improvement is real, but the remaining gap still represents strokes in patients who were already known to have atrial fibrillation. Each of those strokes is a sentinel event that a health system can review.
Pragmatic trials show how hard the gap is to close. The IMPACT-AFib trial enrolled 47,333 patients in U.S. health plans who had a guideline indication for anticoagulation and no recent prescription.[14] At one year, 9.9% of the intervention group and 9.8% of the control group had started an oral anticoagulant, an adjusted odds ratio of 1.01.[14] The authors concluded that more intensive interventions are needed to address underuse.[14]
Detection yields vary with the population and method. A risk model built from electronic health records in five countries identified patients at high risk of new atrial fibrillation.[5] In a prospective study of 1,923 participants, atrial fibrillation was diagnosed in 4.5% of those at high risk compared with 0.6% at low risk.[5] Among high-risk patients whose atrial fibrillation was detected, 96.1% initiated oral anticoagulants.[5] In the related registry, untreated high-risk patients had an ischemic stroke rate of 6.0 events per 100 patient-years.[5]
Quality of care is measurable, and measurement exposes gaps. In U.S. military care, only 41% of encounters for 386 active duty service members with atrial fibrillation reported a CHA2DS2-VASc score, rising to 64% in 2014 to 2019.[9] Of those with indications for long-term anticoagulation, 86% received appropriate therapy, but 31% were inappropriately prescribed both an antiplatelet and an anticoagulant.[9] Those figures show why documentation is not a clerical issue: a missing risk score can mean a missing treatment decision.
Psychological symptoms add risk that many pathways ignore. In two international registries of 12,614 patients, 38.3% were symptomatic for anxiety or depression.[12] Those patients had a higher risk of the composite of death and major adverse cardiovascular events, with a hazard ratio of 1.26, and of cardiovascular death, with a hazard ratio of 1.87.[12] The findings are associations, but they point to an overlooked part of the care model.
Figure 1
Key atrial fibrillation care steps are often incomplete
Percent of patients, encounters or detected cases reaching a recommended care step, as reported in each study. Values are copied from the cited studies [3], [8], [9], [11], [14]; none is estimated.
Data note. Each bar comes from a different study, country, population and definition, so this is an indirect comparison of where the pathway leaks, not a ranking of performance.
Limitation. Documentation and registry measures may not reflect the quality of care delivered; the trial figure applies only to patients not already treated.
Figure data (5 rows)
| Measure | Value | Population, setting and year as reported | Source |
|---|---|---|---|
| Started an oral anticoagulant within one year after mailed education | 9.9% | Intervention group of a U.S. pragmatic trial; patients with an indication and no recent prescription, 2017 to 2019 | [14] |
| Met all three components of integrated care pathway | 20.9% | 699 patients with atrial fibrillation treated in São Paulo, Brazil | [11] |
| Encounters reporting a stroke risk score | 41% | Active duty U.S. service members with atrial fibrillation, 2004 to 2019 | [9] |
| Pharmacy-detected possible cases recommended for medical consultation | 49% | 34 community pharmacies in Nagasaki, Japan | [3] |
| Encounters reporting shared decision-making with a decision aid | 64.7% | U.S. national registry of left atrial appendage occlusion, October 2022 to June 2024 | [8] |

Continuum of care
Where the continuum breaks between detection, decision and follow-up
The atrial fibrillation pathway runs from first detection to confirmation, a stroke prevention decision, treatment start and long-term follow-up. Detection increasingly happens outside the hospital and outside primary care. That shift creates new handoffs that existing referral systems were not designed to receive. Every new entry point needs a defined receiver, a time standard for confirmation and a way to see when a referral stalls.
Community screening illustrates the risk. In 34 community pharmacies in Nagasaki, 123 of 5,371 single-lead ECG recordings (2.29%) indicated possible atrial fibrillation.[3] Pharmacists recommended medical consultation for 60 individuals, or 49% of detected cases, and only a small number of physicians reported encounters with referred patients.[3] The authors called for better referral pathways and coordination between pharmacies and medical institutions.[3]
A Spanish program shows what a closed loop can look like. Among 784 pharmacy users aged 55 or older with cardiovascular risk factors, 62 (7.9%) had an abnormal one-lead ECG, and 36 of those suggested possible atrial fibrillation.[1] Thirty-four were referred to a health center for a 12-lead ECG, and six (17.6%) were diagnosed with atrial fibrillation.[1] The program linked community pharmacies, health centers and auxiliary clinics within one basic health area.[1] That kind of geographic integration is easier for a health system to replicate than a national campaign.
Integrated care after diagnosis matters as much as detection. In São Paulo, Brazil, only 20.9% of 699 patients met all three components of the Atrial Fibrillation Better Care pathway, and only 42.3% had adequate anticoagulation.[11] Integrated care can also reach a ceiling. In a six-country cluster-randomized trial of 1,260 older multimorbid patients, unplanned hospitalization occurred in 17.1% of the intervention group and 18.2% of the usual care group, a difference that was not significant.[10] Baseline anticoagulation was already 97.3%, and 68.5% of patients used the trial app for only one-third of the observation time.[10]
For executives, the lesson is to aim improvement where the gap is largest. In settings with strong baseline adherence, extra layers add little. In settings where anticoagulation and follow-up are weak, a closed referral loop and integrated review are likely to matter more.[11][10] Executives can locate their own system on that spectrum by measuring each step separately rather than relying on a single composite rate.
Figure 3
Why the pathway breaks
People
- Patients uncertain about engaging with referred resources
- Conflicting information from different providers
- Anxiety and depression not assessed
Process
- Pharmacy referrals not received by a designated clinic
- Stroke risk scores not documented
- Antiplatelets prescribed alongside anticoagulants without indication
Technology
- Screening not targeted with health record risk models
- Mobile apps with low sustained use
- Pharmacy and clinic records not linked
Environment
- Social needs such as housing and transportation
- Public and private settings with different strengths
- Detection moving outside traditional clinics
Policy
- Pharmacist services without fair compensation
- Reimbursement rules that do not change decision support practice
- One-way education used in place of redesign
Measurement
- Untreated strokes not reviewed
- Results not stratified by sex, income or site
- Documentation counted instead of decision quality
Unranked qualitative cause-and-effect diagram for the outcome in the box: People with atrial fibrillation have strokes while untreated, or are never confirmed and offered stroke prevention after detection Causes are assembled from the cited literature [2], [3], [5], [6], [7], [8], [9], [10], [11], [12], [14], [15]; categories are not weighted and their order carries no meaning.
Data note. Qualitative; no frequencies are implied.
Limitation. Causes drawn from published studies may not all apply locally; validate them with frontline teams.
Figure data (6 rows)
| Category | Causes drawn from the cited literature |
|---|---|
| People | Patients uncertain about engaging with referred resources; Conflicting information from different providers; Anxiety and depression not assessed |
| Process | Pharmacy referrals not received by a designated clinic; Stroke risk scores not documented; Antiplatelets prescribed alongside anticoagulants without indication |
| Technology | Screening not targeted with health record risk models; Mobile apps with low sustained use; Pharmacy and clinic records not linked |
| Environment | Social needs such as housing and transportation; Public and private settings with different strengths; Detection moving outside traditional clinics |
| Policy | Pharmacist services without fair compensation; Reimbursement rules that do not change decision support practice; One-way education used in place of redesign |
| Measurement | Untreated strokes not reviewed; Results not stratified by sex, income or site; Documentation counted instead of decision quality |
Access
Bringing detection and follow-up closer to where people are
Community pharmacies are among the most accessible points of contact for older adults with cardiovascular risk. They can extend detection beyond scheduled visits, but only if their findings flow into a system that acts on them. Access without a receiving clinic simply moves the gap downstream. Health systems that partner with pharmacies should agree in advance on what happens to an abnormal result, who calls the patient and how quickly a confirmatory visit is offered.
Scale is achievable. In Project IMPACT Cardiovascular Health+, 40 community pharmacies in 20 U.S. states enrolled 2,105 participants and performed 4,037 ECG assessments.[2] Atrial fibrillation readings were present in 4.7% of participants, compared with 1.5% in the general U.S. population, and 55 patients were referred to other providers.[2] Participating pharmacies named fair compensation for pharmacist services as a common barrier to sustainability.[2] Without a payment model, even successful programs may not last beyond a grant or campaign.
Existing equipment can also widen access. Across 212 Slovak pharmacies between 2017 and 2020, routine blood pressure measurement with a monitor that included an atrial fibrillation detection algorithm found suspected atrial fibrillation in 3.8% of adult visitors.[4] The program ran within a nationwide cardiovascular risk awareness campaign, which shows how screening can be layered onto services people already use.[4] Because the devices were already in routine use, detection needed little new equipment, though every suspected case still needed confirmation.
Targeting improves the yield of limited screening capacity. The FIND-AF 2.0 model uses age, sex and 10 comorbidities recorded in electronic health records, and it performed better than two existing risk scores.[5] In its prospective test, high-risk patients had 8.46 times the odds of a new diagnosis compared with low-risk patients.[5] Health systems that already hold these data could direct handheld ECG monitoring to the patients most likely to benefit.
Access also means removing barriers after diagnosis. Social needs, transportation and cost can prevent patients from attending confirmatory visits or filling prescriptions. A screening program that does not plan for those barriers will find patients it cannot treat.[2][6] Navigation support, transportation help and same-week confirmation slots can turn a positive screen into a completed evaluation. Leaders can track the time from a positive community result to a confirmatory test as a simple measure of access.
Executive guidance · System route
Map the path from first contact to verified follow-through.
Use this route as a discussion framework. Replace each stage with the organization’s approved process, qualified roles, current service capacity, and applicable requirements. Do not infer a clinical protocol from the observance title.
The route at a glance
- Listen
- Clarify entry
- Connect the recovery route
- Protect transitions
- Verify and learn
Reliability rule: Every stage needs a named owner, an observable status, an approved escalation path, and a defined signal that shows whether responsibility moved or remained unresolved.
Listen
Gather questions and friction points from people using the route, frontline teams, and community-facing staff. Separate observed barriers from assumptions.
Clarify entry
Publish a plain-language first step and identify who receives requests through each approved channel.
Connect the recovery route
Where locally relevant, make transitions among information, evaluation, services, recovery support, and follow-through visible without prescribing a clinical pathway.
Protect transitions
Use acknowledgment and status visibility when responsibility moves between services, locations, or organizations.
Verify and learn
Review unresolved work, repeat contacts, and avoidable handoffs. Use the findings to improve the route rather than blame individuals.
Figure 2
The system route as one flow
The five stages of the system route described in this brief, drawn as one flow with a learning loop back to the start. The stages are the page’s original executive guidance, not a clinical protocol.
Data note. Shows sequence and handoffs only; it carries no counts or rates.
Limitation. Local processes may add, merge or reorder stages under organizational policy.
Figure data (5 rows)
| Stage | What the stage requires |
|---|---|
| Listen | Gather questions and friction points from people using the route, frontline teams, and community-facing staff. Separate observed barriers from assumptions. |
| Clarify entry | Publish a plain-language first step and identify who receives requests through each approved channel. |
| Connect the recovery route | Where locally relevant, make transitions among information, evaluation, services, recovery support, and follow-through visible without prescribing a clinical pathway. |
| Protect transitions | Use acknowledgment and status visibility when responsibility moves between services, locations, or organizations. |
| Verify and learn | Review unresolved work, repeat contacts, and avoidable handoffs. Use the findings to improve the route rather than blame individuals. |
Equity and trust
Equity gaps in anticoagulation, integrated care and social needs
Atrial fibrillation care is not delivered equally. Differences by sex, income, payer and setting appear at the anticoagulation step and in integrated care. Executives should expect these gaps in their own data and look for them deliberately. Aggregate rates can look acceptable while specific groups receive much less protection from stroke.
Income and sex appear in national data on missed prevention. In the Finnish registry, factors associated with not being on anticoagulation at the time of stroke included lowest income, with an odds ratio of 1.232, and female sex, with an odds ratio of 1.177.[7] Alcohol abuse, liver dysfunction, renal dysfunction and dementia were also associated with non-use.[7] Those patterns suggest that people with complex social and medical needs are more likely to fall out of the prevention pathway.
Similar patterns appear in integrated care. In São Paulo, lack of compliance with the integrated care pathway was associated with female sex, with an adjusted odds ratio of 1.66.[11] Patients treated in public units had worse performance on adequate anticoagulation, with an adjusted odds ratio of 2.50, but better performance on comorbidity treatment than patients using private care.[11] A mixed pattern like this one means equity cannot be judged from a single measure.
Social needs can be identified through partnerships that cross organizational lines. Connect AF linked a health system, five community pharmacies, a payer and an industry partner to screen 75 patients with atrial fibrillation for social needs.[6] Pharmacists provided referrals and resource navigation, and mental health, housing instability and transportation were the most prevalent needs.[6] Most patients expressed uncertainty about engaging with referred resources, which shows that screening for needs is only a first step.[6] Health systems that copy this model should plan for active follow-up, such as warm handoffs and repeat contact, rather than a list of phone numbers.
Stratified reporting turns these findings into action. Leaders can review anticoagulation, referral completion and follow-up by sex, income, payer, language and site, then assign owners for the largest gaps.[7][11] Including patients and community partners in the review helps leaders understand why gaps exist, not just where. That understanding is essential before choosing a fix, because the same gap can have different origins in different communities.

Human infrastructure
The people who make atrial fibrillation pathways work
Atrial fibrillation care relies on a wide team: pharmacists, primary care clinicians, cardiologists, electrophysiologists, nurses and care coordinators. Each holds part of the pathway, and none owns all of it by default. Clear roles and shared protocols determine whether patients move smoothly from one to the next. Workload, scheduling and staffing shortages at any point can slow the whole pathway.
Pharmacists are taking on a larger role in detection and support. In Project IMPACT, pharmacists offered social needs screening, stroke risk assessment, point-of-care ECG testing and assessment for medication therapy management, and 276 patients (13%) were identified with medication-related social needs.[2] In Connect AF, all participating pharmacists reported strong confidence and intent to continue providing social needs support.[6] Their willingness is an asset that health systems can use, provided the referral path is clear. Health systems can formalize that role through collaborative practice agreements and shared documentation.
Physicians and pharmacists must be connected for that asset to count. The Japanese pharmacy program was coordinated by a regional stroke and cardiovascular disease support center, and stakeholders generally found it acceptable and feasible.[3] Yet the gap between detection and medical evaluation remained marked, which points to the receiving side of the handoff.[3] A designated clinic or navigator who accepts pharmacy referrals can close that gap. That role works best when its capacity is sized to the expected referral volume.
Documentation habits shape quality measurement. In the military health system study, shared decision-making about anticoagulation was documented in 82% of cases, and all 115 patients treated with warfarin were appropriately monitored with monthly INR tests.[9] The authors suggested that quality improvement processes could improve risk score reporting, appropriate prescribing and shared decision-making.[9] Measures like these give managers a concrete starting point for coaching and audit, and they show which habits are already reliable.
Teams also need consistent messages. In a Dutch study of 398 patients taking direct oral anticoagulants, conflicting information from different health care providers was a determinant of poorer adherence.[15] The authors recommended reinforced education for both patients and providers, combined with interprofessional collaboration.[15] For executives, that finding supports shared protocols and common patient materials across disciplines. Common materials also save clinician time, because staff do not need to correct one another’s instructions.
Executive guidance · Operating dashboard
Measure whether the operating route works as intended.
Do not publish a number until the organization defines its numerator, denominator where relevant, owner, source system, exclusions, review cadence, and limits. The candidates below are management prompts, not benchmarks or reported results.
Four operating signals
Each signal pairs an executive question with one candidate local measure, set out below.
Executive guidance · Signal
Entry-point clarity
Can people and staff identify the approved first step without searching across conflicting instructions?
- Candidate local measure
- Locally defined contact, routing, and repeat-contact signals by channel and service.
Executive guidance · Signal
Ownership reliability
Does a specific team accept each request and make its status visible?
- Candidate local measure
- Requests without an owner, aged work, transfers, and escalations using locally approved definitions.
Executive guidance · Signal
Recovery-route ownership
Where locally applicable, can people and teams identify the next owner across services and recovery support?
- Candidate local measure
- Locally defined transition acceptance, missing information, unresolved routes, repeat contacts, and experience feedback.
Executive guidance · Signal
Improvement closure
Does the organization correct recurring friction and report what changed?
- Candidate local measure
- Selected barriers, assigned actions, completion status, and post-change review.
Figure 4
The operating system behind the dashboard
The four operating signals from this brief’s dashboard, each tied to the candidate owner named in the executive scorecard, around one accountable route. Drawn from the page’s original executive guidance.
Data note. Structural diagram; no measured values.
Limitation. Owners are candidates to be confirmed locally.
Figure data (4 rows)
| Operating signal | Candidate owner |
|---|---|
| Entry-point clarity | Executive sponsor and operational lead |
| Ownership reliability | Operational owner and participating teams |
| Recovery-route ownership | Sending and receiving owners |
| Improvement closure | Improvement owner and executive sponsor |
Executive guidance · Handoff workflow
Keep work owned when it crosses a boundary.
A handoff is reliable only when the sending party knows who is expected to receive the work, the receiving party acknowledges responsibility, and any unresolved exception remains visible. Local policy and qualified judgment control the actual process.
How responsibility moves
Lane A
From message to accepted ownership
- Confirm the approved message and intended audience.
- Publish the actual entry point and receiving role.
- Acknowledge receipt using the locally approved method.
- Escalate when ownership or response remains unclear.
Lane B
From accepted ownership to verified follow-through
- Record the next accountable owner and visible status.
- Confirm the receiving owner and next contact across services or recovery support where locally applicable.
- Keep unresolved work visible across boundaries.
- Confirm closure or document the continuing exception.
Executive guidance · Executive scorecard
Ask questions that connect intent, ownership, and results.
The scorecard keeps review focused on decisions. Leaders should set definitions locally, examine variation without overclaiming cause, and pair quantitative signals with the experience of people who use and operate the route.
Who reviews what
- Executive sponsor and operational lead
- Operational owner and participating teams
- Sending and receiving owners
- Improvement owner and executive sponsor
Candidate owners named in the scorecard, confirmed locally.
| Operating signal | Executive question | Candidate owner | Suggested review point |
|---|---|---|---|
| Entry-point clarity | Can people and staff identify the approved first step without searching across conflicting instructions? | Executive sponsor and operational lead | At campaign launch and close |
| Ownership reliability | Does a specific team accept each request and make its status visible? | Operational owner and participating teams | At a locally defined cadence |
| Recovery-route ownership | Where locally applicable, can people and teams identify the next owner across services and recovery support? | Sending and receiving owners | At a locally defined cadence |
| Improvement closure | Does the organization correct recurring friction and report what changed? | Improvement owner and executive sponsor | Until action is verified |
Figure 5
Control points for a reliable atrial fibrillation stroke prevention pathway
| Control point | Risk if missing | Owner | Evidence of control |
|---|---|---|---|
| Designated receiving clinic for community and pharmacy screening results | Detected cases are never confirmed or treated | Cardiology service line leader with primary care | Share of referred cases with a confirmatory evaluation |
| Stroke risk score documented for every patient with atrial fibrillation | Treatment decisions lack a consistent basis | Ambulatory quality lead | Share of encounters with a documented risk score |
| Review of every stroke in a patient with known atrial fibrillation not on anticoagulation | Missed prevention is never examined | Chief medical officer and stroke program director | Case review completion and actions assigned |
| Decision support process audited by clinician and site | Shared decision-making varies by institution and becomes a checkbox | Electrophysiology and quality leaders | Variation in documented decision aid use by clinician |
| Health record risk model used to target screening | Limited screening capacity spent on low-yield groups | Chief medical information officer | Yield of new diagnoses per screening episode |
| Social needs and mental health screening linked to referral | Patients with needs fall out of treatment | Care management and behavioral health leads | Share screened, referred and engaged |
| Equity review of anticoagulation by sex, income and site | Gaps persist unseen in aggregate rates | Health equity officer and board quality committee | Stratified anticoagulation rates reviewed each quarter |
Control points derived from the cited evidence [1], [3], [5], [6], [7], [8], [9], [11], [12] and this brief’s executive guidance.
Data note. Each row is a control to verify, not a measured result.
Limitation. Owners and evidence of control must follow local policy and applicable requirements.
Public communication
Communicating so that patients can make and keep a decision
Stroke prevention in atrial fibrillation depends on decisions that patients must understand, accept and sustain. Communication therefore needs to support a real choice, not just deliver a recommendation. It also needs to continue after the first visit. Patients may receive results from a pharmacy, a wearable device or a clinic, and each message should point to the same next step.
Information alone has limits. In the IMPACT-AFib trial, a single mailing to patients and clinicians did not change anticoagulant initiation.[14] That result suggests that one-way messages, however accurate, may not shift decisions without a conversation and a clear next step. Communication budgets may be better spent on navigators and decision support than on printed material alone.
Shared decision-making is increasingly expected, but its quality varies. In a national U.S. registry of 147,296 left atrial appendage occlusion encounters, 64.7% reported shared decision-making with a decision aid, rising from 62.5% in October 2022 to 75.0% in June 2024.[8] The estimated probability of reporting both varied by institution from 0.1% to 76.4%, and patients with Medicare did not have greater odds of reported use despite a federal reimbursement requirement.[8] The authors attributed most of that variation to the institutional level.[8] Leaders can ask for the same variation data from their own programs, by clinician and site.
Patients describe gaps that clinicians may not see. In a mixed-methods study of 15 patients and five clinicians, patients considering catheter ablation reported low levels of information and agency, even though most clinicians reported routinely providing information.[13] Patients preferred an interactive decision aid with data, visualizations, videos and personalized risk estimates, available in multiple languages.[13] Poor shared decision-making was also associated with suboptimal adherence to direct oral anticoagulants.[15] Those gaps between what clinicians intend and what patients experience are a practical target for communication redesign.
Trust grows when communication is consistent and attentive to the whole person. Anxiety and depression are common in this population and are associated with worse outcomes, so communication plans should include psychological assessment and support.[12] Health systems can use this month to publish a clear route from screening result to decision and follow-up, and to report back on what changed. That report should include what was measured, what improved and what still needs work.

Executive guidance · 90-day plan
Move from listening to a verified improvement in 90 days.
The time boxes below are a management framework, not a clinical timeline. Adjust them to risk, scope, governance, resources, stakeholder participation, and applicable review requirements.
Ninety days, three moves
- Days 1–30See the current route
- Days 31–60Build the reliable path
- Days 61–90Make the change visible
Days 1–30 · Listen and map
See the current route
- Name an executive sponsor and an operational owner.
- Listen to people using the route and representative frontline teams.
- Map how National Atrial Fibrillation Awareness Month communications connect to real entry points, owners, transitions, and escalation.
- Select one recurring barrier that the organization can responsibly address.
Days 31–60 · Design and test
Build the reliable path
- Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal.
- Validate the design with every sending and receiving team involved.
- Review one locally relevant service-to-recovery handoff and verify that ownership remains visible.
- Test the route in more than one representative setting or operating period where practical.
Days 61–90 · Implement and verify
Make the change visible
- Launch the redesigned route with a small set of locally defined measures.
- Review unresolved work and recurring friction using a learning approach.
- Correct implementation barriers and record who owns each remaining dependency.
- Report what changed, what evidence was reviewed, and what still requires live oversight.
Figure 6
The 90-day plan on one timeline
The 90-day plan from this brief drawn as a timeline: each action sits in the 30-day window the plan assigns it. The full wording of each action is in the figure data and in the plan above.
Data note. Time boxes are a management framework, not a clinical timeline.
Limitation. Durations are uniform 30-day windows; real tasks may span windows.
Figure data (12 rows)
| Window | Action |
|---|---|
| Days 1–30 · Listen and map | Name an executive sponsor and an operational owner. |
| Days 1–30 · Listen and map | Listen to people using the route and representative frontline teams. |
| Days 1–30 · Listen and map | Map how National Atrial Fibrillation Awareness Month communications connect to real entry points, owners, transitions, and escalation. |
| Days 1–30 · Listen and map | Select one recurring barrier that the organization can responsibly address. |
| Days 31–60 · Design and test | Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal. |
| Days 31–60 · Design and test | Validate the design with every sending and receiving team involved. |
| Days 31–60 · Design and test | Review one locally relevant service-to-recovery handoff and verify that ownership remains visible. |
| Days 31–60 · Design and test | Test the route in more than one representative setting or operating period where practical. |
| Days 61–90 · Implement and verify | Launch the redesigned route with a small set of locally defined measures. |
| Days 61–90 · Implement and verify | Review unresolved work and recurring friction using a learning approach. |
| Days 61–90 · Implement and verify | Correct implementation barriers and record who owns each remaining dependency. |
| Days 61–90 · Implement and verify | Report what changed, what evidence was reviewed, and what still requires live oversight. |
Executive guidance · Leadership close
Carry one accountable improvement beyond the campaign window.
Recognition matters. It becomes durable when leaders also listen, clarify the route, support the people operating it, close an identified gap, and report the result without claiming more than the evidence supports.
Leadership commitment
Listen to the people closest to the route, assign one barrier, and verify the change.
Executive action kit · Month observance
Turn National Atrial Fibrillation Awareness Month into accountable action.
Use the observance to review how people find information, enter the right route, and remain connected through follow-through.
Leadership focus
Use this observance to examine navigation, longitudinal ownership, and specialty-care coordination. Select one verified barrier, assign an accountable owner, and carry the improvement beyond the campaign window.
Workforce lens
Ask whether staffing, role clarity, training, tools, workload, and escalation support the people operating the information, acute-to-ambulatory transition, rehabilitation, and follow-through pathway.
Patient and community lens
Make the approved first step clear. Test whether a person can move from information to an acknowledged next action without navigating conflicting instructions.
Equity and access lens
Review transportation, language, digital access, affordability, geography, disability, and whether the recovery route works across different settings.
Five-minute briefing
Inspect the operating sequence
Listen with patients, caregivers, cardiovascular teams, rehabilitation, pharmacy, and ambulatory partners. Find one an unowned transition, unclear recovery route, or unresolved access need, then test the locally approved route from entry through acknowledged follow-through.
- Listen
- Clarify entry
- Connect the recovery route
- Protect transitions
- Verify and learn
Leadership actions for this week
- Name an executive sponsor and frontline operating owner.
- Ask people using and operating the pathway where ownership becomes unclear.
- Test one representative route from first question to acknowledged next step.
- Select one barrier that can be corrected without overstating the evidence.
- Set a review date and define how completion will be verified.
Candidate measures
Define every numerator, denominator where relevant, owner, data source, exclusions, cadence, and limitation locally. These are management prompts, not external benchmarks.
- Locally defined contact, routing, and repeat-contact signals by channel and service.
- Requests without an owner, aged work, transfers, and escalations using locally approved definitions.
- Locally defined transition acceptance, missing information, unresolved routes, repeat contacts, and experience feedback.
Department readiness checklist
- The public and staff entry points match the actual approved process.
- A specific role accepts each request, referral, or escalation.
- Handoffs include acknowledgment and a visible unresolved state.
- Language, disability, digital, transportation, and trust barriers receive explicit review.
- Communications do not introduce unsupported themes, statistics, or clinical advice.
- A named leader will review what changed after the observance.
Intended audiences
- Executive and Operational Leaders
- Patient Experience and Access Leaders
Staff communication template
During National Atrial Fibrillation Awareness Month, our organization will connect awareness with a practical review of the information, acute-to-ambulatory transition, rehabilitation, and follow-through pathway. Use approved information, identify the correct entry point, confirm ownership when work moves, protect privacy, and escalate unresolved barriers through local channels.
Community communication template
National Atrial Fibrillation Awareness Month is an opportunity to share trustworthy information and make the next step easier to find. Use our approved channels for information and support. If a request changes hands, our goal is to keep ownership and follow-through visible.
Measurement worksheet
- Signal
- What observable condition will show whether the route works?
- Definition
- What is included, excluded, and counted?
- Owner
- Who reviews the signal and acts on exceptions?
- Cadence
- When will leaders review it?
- Equity check
- Which differences require protected, locally appropriate review?
- Closure
- What evidence will confirm the improvement was completed?
- Editorial review
- Completed
- Source records
- 2 listed under Authoritative resources
- Review standard
- Sourced facts remain separated from original executive guidance
- Clinical boundary
- No new statistical or clinical claim was added by this action kit
Sources and content boundary
Authoritative resources
Use note: All operating models, measures, scorecard questions, and action steps are original executive guidance. This article supports leadership planning and education. It does not replace clinical judgment, emergency procedures, legal advice, professional standards, organizational policy, or applicable federal, state, and local requirements.
Peer-reviewed references
References
Fifteen peer-reviewed sources, newest first. Each was individually verified through authenticated academic research databases. Bracketed numbers in the text link here; the original executive guidance on this page carries no citations because it is guidance, not a sourced claim. Sources last checked in those databases on .
- 1.García Agudo Ó, Fuertes González R, García Gil M, Gómez Cotino E, Villalba Montejano M, Peláez Ferrando Á, et al. Screening for undiagnosed atrial fibrillation in community pharmacies using mobile electrocardiogram technology: a quasi-experimental cross-sectional study (PREVENIM ICTUS). BMC Primary Care. 2026;27(1). https://doi.org/10.1186/s12875-026-03188-7
- 2.Bluml BM, Little J, Bennett M, Scovis N, Bonham AJ. Project IMPACT Cardiovascular Health+: Pharmacy services for better cardiovascular health. Journal of the American Pharmacists Association. 2026;66(5):103467. https://doi.org/10.1016/j.japh.2026.103467
- 3.Sakamoto T, Tateishi Y, Kurobe M, Yahata H, Miyakoda M, Kodama Y, et al. Pharmacy-Based Atrial Fibrillation Screening Model Coordinated by a Regional Stroke and Cardiovascular Disease Support Center: The Catch AF Project. Circulation Reports. 2026;8(7):1131-1140. https://doi.org/10.1253/circrep.cr-26-0109
- 4.Stanko P, Macekova Z, Zufkova V, Snopkova M, Klimas J, Fazekas T. Blood Pressure Monitors in Screening of Atrial Fibrillation by Community Pharmacists: Data from a Nationwide Awareness Campaign. Bratislava Medical Journal. 2026;127(7):3023-3033. https://doi.org/10.1007/s44411-026-00692-1
- 5.Nadarajah R, Wu J, Wahab A, Reynolds C, Haris M, Joseph T, et al. Risk-Guided Screening for Atrial Fibrillation Using Electronic Health Records. Circulation. 2026;154(8):707-717. https://doi.org/10.1161/circulationaha.126.079391
- 6.Liang D, Witkowski M, Abolins N, Rush J, Naper K, Gardin V, et al. Pharmacist-led community network approach addressing social needs and adherence (Connect AF). Journal of the American Pharmacists Association. 2026;66(4). https://doi.org/10.1016/j.japh.2026.103123
- 7.Vilpponen M, Aro AL, Halminen O, Tiili P, Linna M, Luojus A, et al. Factors associated with oral anticoagulant non-use at first ischemic stroke in atrial fibrillation: A nationwide study. European Stroke Journal. 2026;11(1). https://doi.org/10.1093/esj/23969873251343857
- 8.Rager JB, Huang CY, Zimmerman S, Dhruva SS, Freeman JV, Matlock DD, et al. Shared Decision-Making and Patient Decision Aids for Percutaneous Left Atrial Appendage Occlusion. JAMA Network Open. 2026;9(2):e2556937. https://doi.org/10.1001/jamanetworkopen.2025.56937
- 9.Keithler AN, Tunzi MA, Wilson AS, Bush KNV. Clinical Performance and Quality Measures of Atrial Fibrillation Management for Active Duty Military Personnel in the U.S. Military Health System. Military Medicine. 2026;191(5/6):e1033-e1038. https://doi.org/10.1093/milmed/usaf524
- 10.Lip GYH, Johnsen SP, Maggioni AP, Gamble C, Tokmakova MP, Frost L, et al. Integrated care management and comprehensive geriatric assessment using a mHealth-based approach in older multimorbid patients with atrial fibrillation: the AFFIRMO cluster-randomised trial. The Lancet Regional Health - Europe. 2026;70. https://doi.org/10.1016/j.lanepe.2026.101832
- 11.Santos IS, Goulart AC, Olmos RD, Varella AC, Quintino CR, Gebara OCE, et al. Compliance with the ABC pathway for integrated care of patients with atrial fibrillation in Brazil: a retrospective cohort study. Expert Review of Cardiovascular Therapy. 2026;24(6):549-558. https://doi.org/10.1080/14779072.2026.2686161
- 12.Rossi M, Bucci T, Tartaglia E, Askarinejad A, Rigutini AG, Tse HF, et al. Impact of anxiety and depression in patients with atrial fibrillation: Insights from 2 international prospective registries. Heart Rhythm. 2026;23(10):e2488-e2498. https://doi.org/10.1016/j.hrthm.2026.06.001
- 13.Turchioe MR, Mangal S, Ancker JS, Gwyn J, Varosy P, Slotwiner D. ‘Replace uncertainty with information’: shared decision-making and decision quality surrounding catheter ablation for atrial fibrillation. European Journal of Cardiovascular Nursing. 2023;22(4):430-440. https://doi.org/10.1093/eurjcn/zvac078
- 14.Pokorney SD, Cocoros N, Al-Khalidi HR, Haynes K, Li S, Al-Khatib SM, et al. Effect of Mailing Educational Material to Patients With Atrial Fibrillation and Their Clinicians on Use of Oral Anticoagulants: A Randomized Clinical Trial. JAMA Network Open. 2022;5(5):e2214321-e2214321. https://doi.org/10.1001/jamanetworkopen.2022.14321
- 15.Moudallel S, van den Bemt BJF, Zwikker H, de Veer A, Rydant S, Dijk LV, et al. Association of conflicting information from healthcare providers and poor shared decision making with suboptimal adherence in direct oral anticoagulant treatment: A cross-sectional study in patients with atrial fibrillation. Patient Education and Counseling. 2021;104(1):155-162. https://doi.org/10.1016/j.pec.2020.06.016
Claim-to-source matrix
What each source supports
Every sourced claim in the new sections maps to the references that support it, the section where it is used, and the limitation a reader should keep in mind. Original executive guidance carries no sources because it is guidance, not a finding.
| Claim group | Sources | Years | Used in | Limitation |
|---|---|---|---|---|
| Anticoagulant non-use at first ischemic stroke and associated factors | [7] | 2026 | Current evidence | Finnish registry data from 2007 to 2017; associations only; national practice has changed since. |
| Mailed education and anticoagulant initiation | [14] | 2022 | Current evidence | Single mailing within U.S. health plans; claims-based outcome. |
| Risk-guided screening using electronic health record data | [5] | 2026 | Access | Prospective test in selected sites with handheld ECG; stroke rate estimated from a separate registry. |
| Quality measures of atrial fibrillation care | [9] | 2026 | Current evidence | Active duty military population of 386 people; retrospective records from 2004 to 2019. |
| Anxiety and depression and outcomes in atrial fibrillation | [12] | 2026 | Current evidence | Post hoc registry analysis; associations, not effects of treatment. |
| Pharmacy screening and the gap to medical follow-up | [1] [3] | 2026 | Continuum of care | Regional programs in Japan and Spain; short study periods and small confirmed case counts. |
| Integrated care pathway compliance and mobile integrated care | [10] [11] | 2026 | Continuum of care | Retrospective cohort in one Brazilian city; trial in a highly adherent European population with low app use. |
| Scaled pharmacy cardiovascular services and sustainability | [2] | 2026 | Access | Descriptive U.S. practice project; comparison with national prevalence is not adjusted. |
| Opportunistic detection with blood pressure monitors in pharmacies | [4] | 2026 | Access | Retrospective campaign records from Slovak pharmacies; suspected, not confirmed, atrial fibrillation. |
| Social needs screening through cross-sector pharmacy partnership | [6] | 2026 | Equity and trust | Seventy-five patients at five pharmacies; descriptive feasibility data. |
| Shared decision-making and decision aid use across institutions | [8] | 2026 | Public communication | Registry-reported documentation for one procedure; reporting may not reflect decision quality. |
| Patient and clinician experience of ablation decisions | [13] | 2023 | Public communication | Fifteen patients and five clinicians in a cross-sectional mixed-methods study. |
| Conflicting information, shared decision-making and anticoagulant adherence | [15] | 2021 | Human infrastructure | Self-reported adherence in a Dutch cross-sectional survey. |

About the author
Greg Wahlstrom
MBAHCM
President and Chief Executive Officer, The Healthcare Executive
View Greg’s profile©2014 – 2026 The Healthcare Executive. All rights reserved.

